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Objeca'ves. We examined the antianginal and anti-ischemie 
effects of oral zatebradine, a direct sinus node inhibitor that has 
no blood pressure-lowering or negative inotropic effects in pa- 
tients with chronic stable angina pectoris taking extended-release 
nifediplne. 
Background. Heart rate reduction is considered an important 
pharmacologic mechanism for providing anginal pain relief and 
anti-isehemic action in patients with chronic stable angina, sug- 
gesting a benefit for sinus node.inhibiting drugs. 
Methods. In a single-blind placebo run-in, randomized double- 
blind, placebo-controlled, multicenter study, patients already 
receiving extended-release nifedipine (30 to 90 mg once a day) 
were randomized to receive zatebradine (5 mg twice a day In = 
64]) or placebo (n = 60). All subjects had reproducible treadmill 
exercise-induced angina at baseline, and after randomization they 
performed a serial exercise test 3 h after each dose for 4 weeks. 
Results. Zatebradine reduced rest heart rate both at 4 weeks 
([mean ± SEM] 12.9 - 1.23 vs. 23 ± 1.6 [placebo] beats/min, 
p < 0.0001) and at the end of comparable stages of Brace exercise 
(16.7 -- 1.2 vs. 3A ± 1.2 [placebo] beats/min, p < 0.0001). Despite 
the significant effects on heart rate at rest and exercise, there were 
no additional benefits of zatebradine from placebo baseline in 
measurements of total exercise duration, time to l-ram ST seg- 
ment depression or time to onset of angina. Subjects taking 
zatebradine also had more visual disturbances as adverse reac- 
tions. 
Conclusions. Zatebradine seems to provide no additional anti- 
anginal benefit to patients already receiving nifedipine, and it 
raises questions regarding the benefit of heart rate reduction 
alone ~-s an antianginal approach to patients with chronic stable 
angina. 
(J Am Con Cardiol 1995;26:305-12) 
Heart rate reduction at rest and during exercise has been 
considered an important mechanism for the antianginal and 
anti-ischemic effects of beta-adrenergic blocking agents and 
the rate-lowering calcium channel blocking agents diltiazem 
and verapamil (1-3). A new class of drugs--the direct sinus 
node inhibitors--has been developed. These drugs have bra- 
dycardic actions without effects on myocardial contractility, 
blood pressure or peripheral nd coronary vascular resistances 
(4-7). 
Zatebradine (Fig. 1), a prototype agent of this class, has 
been shown (8,9) to reduce heart rate at rest and during 
exercise in humans. We report the results of a multicenter, 
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randomized, ouble-blind, placebo-controlled trial designed to 
investigate whether exercise tolerance could be favorably 
affected by the addition of zatebradine inpatients with angina 
pectoris whose exercise tolerance is limited despite treatment 
with 30 to 90 mg of extended-release nifedipine (Procardia 
XL). A secondary objective was to assess the safety profile of 
concomitant zatebradine and nifedipine administration. 
Methods  
Patients with stable exertional angina who were already 
receiving 30 to 90 rag/day of extended-release nifedipine were 
enrolled in this double-blind, randomized, placebo-controlled 
trial at 17 separate centers (see Appendix). The trial was 
approved by the appropriate institutional review board at each 
participating center. All subjects signed a written consent form 
that fully explained the purposes and potential risks and 
benefits of participation i the study. 
Study patients. Patients (150 men, 25 women; age range 30 
to 82 years) had a _>3-month history of chronic stable angina 
triggered by physical activity and relieved by rest or nitroglyc- 
erin. Study inclusion required electrocardiographic (ECG) 
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Figure 1. Chemical structure ofzatebradine. 
evidence of exercise-induced myocardial ischemia (ST segment 
depression >-1 mm from baseline) or documented angio- 
graphic evidence of coronary artery disease, or both. Patients 
with conditions that would hinder or confuse follow-up evalu- 
ations and those unable to undergo the protocol requirements 
for the study were excluded. 
Study design. This was a multicenter, double-blind, ran- 
domized, parallel-group comparison of 5 mg of zatebradine 
and placebo administered orally twice a day in patients with 
chronic stable angina pectoris whose exercise tolerance was 
limited despite treatment with 30, 60 or 90 mg of extended- 
release nifedipine administered once a day. With the exception 
of nifedipine and sublingual nitroglycerin, as needed for the 
relief of attacks of angina, ne other antianginal therapy was 
allowed at any time during the study. 
The study design is described in Figure 2. Qualifying 
patients were enrolled in a run-in phase consisting of 3 to 4 
visits over a 2- to 3-week period, during which they received 
placebo twice a day. Patients performed two consecutive 
treadmill exercise tests according to the standard Bruce pro- 
tocol. To qualify the patient for randomization, both exercise 
tests had to be between 4 and 9 min long, be limited by 
moderate angina and show ST segmeni depression of at least 
0.1 mV in at least one ECG lead. In addition, the duration of 
the shorter of the two tests had to be within 15% of the 
duration of the longer test. If these criteria were not met on the 
first two tests, a third exercise test could be scheduled 1 week 
after the second test. 
After randomization, patk:nts received a single dose of 
double-blind study medication i the ciinic, and heart rate and 
blood pressure were monitored for 3 h after dosing. No 
patients were excluded from participation i the study because 
of excessively low blood pressure (-<80/60 mm Hg) or excessive 
bradycardia (---40 beats/min) after the first dose. Visits were 
Figure 2. Study design. Ex. = exercise. 
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scheduled after 1, 2 and 4 weeks of double-blind treatment. 
During these visits, exercise tests were performed 3 h 
(+_30 rain) after the morning dose of extended-release nif di- 
pine and double-blind study medication. 
Throughout the trial, patients kept a diary documenting the 
number of anginal attacks experienced and number of nitro- 
glycerin tablets taken. During the follow-up exercise tests, time 
to angina was recorded both at onset of angina and at 
moderate xercise angina (the degree of angina at which the 
patient would normally stop exercising and take nitroglycerin), 
This was done uniformly throughout the study centers. Elec- 
trocardiographic strips for determining ST segment depression 
were recorded while the patients were standing on the tread- 
mill, before exercise, at the end of each minute of exercise, at 
the onset of angina nd at the end of exercise. 
A 48-h ambulatory ECG was recorded, and an ophthalmo- 
logic examination was performed uring the placebo run-in 
period and at the end of the study. 
Statistical considerations. Data are presented as mean 
value _+ SEM. The basic statistical model for the present study 
was an analysis of the change from baseline of a given variable 
using ordinary least squares (SAS Type II). Zatebradine was 
compared with placebo by a one-way analysis of covariance 
model that included treatment group, trial center and baseline 
exercise duration. Other baseline covariates that were found to 
be prognostic of change in exercise duration in the blinded 
data and therefore included irl the model were age, gender, 
weight and current smoking status. All efficacy analyses were 
based on the so-called last observation carried forward data 
set, in which the last a~,ailable values after randomization were 
carried forward for patients who failed to complete an exercise 
test at week 2 or 4. Only two patients, o~',e in each group, had 
data carried forward to the week 4 time point. Exercise 
duration was substituted for time to ST segment depression or
time to onset of angina when these end points did not occur 
after randomization. The planned sample size of 60 patients/ 
treatment group was chosen to detect a60-s difference in total 
exercise duration with 90% power at the 5% two-sided signif- 
icance level, assuming a standard eviation of 100 s. 
Results  
Patient disposition and demography. A total of 124 pa- 
tients completed screening and qualified for randomization. 
Four patients who were assigned to receive placebo were not 
able to complete the study because of adverse vents (worsen- 
ing angina, congestive heart failure). The demographics of the 
placebo and zatebradine treatment groups are described in 
Table 1. Of those patients randomized, 80% were men; 68% 
had Canadian Cardiovascular Society class II and 32% class II 
or II1 angina pectoris. The mean (_+SEM) duration of angina 
pectoris was 7 years (range 0.3 to 25). All patients had ob- 
jective evidence of coronary artery disease (previously docu- 
mented myocardial infarction or positive findings on coronary 
angiography, scintigraphy or stress echocardiography). Coro- 
nary angiography ad been performed in 96 patients, 93% of 
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Table 1. Pertinent Patient Characteristics at Baseline 
Zatebradine 
Placebo (5.0 mg bid) 
(n = 60) (n = 64) 
Gender 
Male 51 (85) 48 (75) 
Female 9 (15) 16 (25) 
Age (yr) 
Mean (SD) 62.3 (8.3) 63 (9.6) 
Range 37-80 30-82 
Race 
White 53 (88) 56 (88) 
Black 2 (3) 5 (8) 
Other 5 (9) 3 (4) 
Height (in.) 
Mean (SD) 68.6 (3.9) 669 (3.6) 
Range 60-76 59-74 
Weight (lb) 
Mean (SD) 181.8 (35.3) 181.7 (34.8) 
Range 119-328 104-306 
Evidence of CHD 
Myocardial infarction 26 (43) 30 (47) 
Imaging 33 (55) 28 (44) 
Ed~ocardiogram 7 (12) II (17) 
Coronary angiography 47 (78) 49 (77) 
At least one of these factors 60 (100) 64 (100) 
Risk factors 
Hypertension 29 (48) 30 (47) 
Hypcrlipidemia 43 (72) 47 (73) 
Hypcruricemia 5 (8) 0 (0) 
Diabetes mellitus 9 (15) 17 (27) 
Previous moker 39 (65) 39 (61) 
Current smoker 8 (13) 5 (8) 
Oral contraceptive use 1 (2) 3 (5) 
At least one of these factors 56 (93) 58 (91) 
Duration of angina (yr) 
Mean (SD) 8.2 (5.8) 6.7 (5.6) 
Range 0.3-25 0.3-23 
Canadian Cardiovascular 
Society class 
II 41 (68) 43 (67) 
II or I11 19 (32) 21 (33) 
Baseline nifedipine, total daily 
dose (rag) 
30 40 (67) 35 (55) 
60 18 (30) 21 (33) 
90 2 (3) 8 (13) 
Data presented are number (%) of patients, unless otherwise indicated. 
bid = twice daily; CHD = coronary heart disease. 
whom showed at least 60% diameter narrowir, g in at leas' one 
major coronary artery. None of the differences observed in 
demographics of clinically important baseline characteristics 
between the two treatment groups reached statistical slgnifi- 
canoe. 
The treatment groups were well ba!anced at baseline with 
respect o age, dose of nifedipine, Canadtan Cardiovascular 
Society classification of severity of a,agina nd total exercise 
duratien (Table 1). Slight baseline imbalances in the number 
of anginal attacks, number of women and time to 0.1-mV ST 
segment depression were taken into account in the analysis. 
The dose distribution of extended-release nifedipine 
throughout the study was as follows: 75 patients received 
30 mg, 39 received 60 mg, and 10 received 90 mg. 
One patient did not reach the primary end point of 
moderate exercise-induced angina pectoris at either qualifying 
exercise test. This patient also did not reach ST segment 
depression of at least 0.1 mV. The data for this patient were 
excluded from all efficacy analyses hut were included in all 
safety analyses. 
Efficacy response variables. Exercise duration. Data sum- 
marizing the exercise test findings for both treatment groups at 
weeks 1, 2 and 4 appear in Table 2. The data proved less 
variable, with the residual standard deviation ranging from 57 s 
at week 1 to 74 s at week 4. With b4 evaluable patients 
receiving zatebradine and 58 placebo, the detectable differeace 
at week 4 was 44 s with 90% power, 38 s with 80% power and 
26 s with 50% power. The difference between the zatebradine 
and placebo treatme~lt groups in mean exercise duration alter 
4 weeks of treatment was only 3 s. Similar results were 
observed for time to onset of l-ram ST segment depression and 
time to onset of angina (Fig. 3). 
At 4 weeks, exercise times were simila~ m both placebo and 
zatebradine treatment ,~,~ps because" -20% of patients in 
both treatment groups hau improved their exer ~se duration 
>-20% from baseline. 
Heart rate and blood pressure data. The effects af. atebra- 
dine and placebo n heart rate at rest and during ex,,cise are 
sho~n in Table 3. Heart rate at rest and during exercise was 
significantly lower in the zatebradine group than in the placebo 
group (p < 0.0001). Heart rate was reduced by 11 to 13 
beats/min at rest and by 13 to 14 beats/min at the end of the 
last comparable xercise stage. There were no significant 
changes in rest and exercise blood pressure variables with 
either placebo r zatebradine (Table 4). 
Anginal attack rate and nitroglycerin consumption. At base- 
line, patients in the zatebradine group had 1.59 +- 0.32 anginal 
attacks/week and were taking 0.73 - 0.17 nitroglycerin tablets/ 
week. Subjects in the placebo group had 2.53 +- 0.42 anginal 
attacks/week and were taking 1.48 - 0.73 nitroglycerin tablets/ 
week. After 4 weeks of treatment, there was a small but 
significant reduction in anginal attacks and nitroglycerin con- 
sumption in the zatebradine group compared with the placebo 
group (Table 5). 
Adverse effects. Clinically significant adverse vents oc- 
curred in two patients during the course of the study. Four 
patients (3.2%), including the two with serious adverse vents, 
were dropped from the trial due to adverse vent~. All four 
were hi the placebo run-in treatment group. There were no 
deaths in the study. 
The most frequent adverse ffect in the zatebradine treat- 
ment group was visual phenomena, reported by 19 patients 
(20.7%); only two patients (3.3%) reported visual phenomena 
in the placebo group. In eight patients receiving zatebradine, 
these visual phenomena persisted from 2 to 9 days after 
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Table 2. Least-Squares Analysis of Exercise Tolerance Test Variables: Placebo (n = 58) Versus 
Zatebradine (5 rag, n = 64) Treatment 
Baseline Change From Baseline 
Mean SE Mean SE Adj Mean* Tx Effect* p Value? 
Total Exercise Duration (s) 
Week I 
Placebo 
Zatebradine 
Week 2 
Placebo 
Zatebradine 
Week 4 
Placebo 
Zatebradine 
395 9.7 9 7.8 17 
390 11.4 29 7.5 36 !9 0.089 
395 9.7 19 9.5 25 
390 1i.4 34 7.0 36 12 0.31 
395 9.7 27 11.8 37 
390 11.4 35 8.0 40 3 0.85 
Time to 0.I-mVST Segment Depression (s) 
Week 1 
Placebo 329 10.9 
Zatebradine 301 12.7 
Week 2 
Placebo 329 10.9 
Zatebradine 301 12.7 
Week 4 
Placebo 329 10.9 
Zatebradine 301 12.7 
8 9.4 14 
48 lq.0 47 33 0.017 
22 9.6 24 
4~ 9.7 40 16 0.20 
25 11.9 37 
40 10.2 46 9 0.57 
Time to Onset of Angina (s) 
Week 1 
Placebo 313 10.6 16 9.2 23 
Zatebradin¢ 298 11.0 35 9.9 35 12 0.38 
Week 2 
Placebo 313 10.6 14 10.9 20 
Zatebradine 298 11.0 42 10.2 40 20 0.16 
Week 4 
Placebo 313 10.6 32 13.4 47 
Zatebradine 29~ 11.0 43 13.0 46 -1 0.97 
*Adjusted (Adj) for trial center and baseline, t'Zatebradine v rsus placebo. Tx = treatment. 
discontktuation [ the drug in six patients and much longer in 
tWO. 
The most frequent side effect in the placebo group was 
dizziness, reported by four patients (6.7%); only one patient 
(1.6%) repotted izziness ia the zatebradine group. 
Ophthalmologic examinations revealed clinically significant 
changes from baseline in only two patients; one patient in the 
plaee,~o group/tad/alepharitis, andone patient irt the zatet~ra- 
dine group had increased intraocular pressure (glaucoma). 
Data from 48-h ambulatory ECG monitoring showed no 
significant increase in arrhythmia in either treatment groap, 
and zatebradine did not demonstrate a proarrhythmic effect 
~c, ord~g ~o the p~edefi~eet cri eria. 
There were no clinicaUy significant changes in PR, QRS or 
QT intewals in either treatment group, although the mean 
~c~ege'~ ~a~rt, ~,cce'(me -we,:e in some cases ~a~'lSficdhy sigiffn- 
eantly different from placebo. The increased QT intervals in 
the zalebradine group were consistent with the bradycardic 
c'ffx~asf,dr~ ~d-t ug, 
There were no clinically relevant mean changes /tom 
baseline in any of the laboratory variables measured. 
Discussion 
The patients in our study had mild to moderate angina, and 
despite some modest reductions inepisodes of angina pectoris 
with the use of zatebradine, there ,,vere Go effects of treatment 
on any of the exercise response variables. At the same time 
there were significant effects of zatebradine on rest and 
exercise heart rate, consistent with the pharmacologic a tivity 
of the drug. 
The lack oI an etfec`t on exercise "tolerance in "the presen"t 
study with zatebradine conflicts with previous animal and 
clinical studies performed in Europe (8-10). In the largest 
European 151ac6oo-contrdfled e~cacy and dose:and'rag tfldl 
(162 patients), 5 mg twice a day of zatebradine was shown to be 
effective in relieving angina pectoris episodes and improving 
exercise tdlerance compare~ wttn 151ac~Do ~(9). "file ~lru~'s 
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effect on heart rate was similar to that found in our study. How- 
ever, there was a much less impressive placebo treatment effect 
shown in the European study (9), and its active treatment 
phase was only 2 weeks (9). In two recent double-blind studies 
Figure 3. Adjusted mean changes from baseline in exercise dura- 
tion (left); time to 0.1-mV ST segment depression (center); and 
time to onset of angina (right). At 4 ~eeks there were significant 
differences in the treatment groups. PBO = placebo plus nifedipine; 
5 MG = zatebradine plus placebo. 
Table 3. Effect of Placebo and Zatebradine (5 mg) on Heart Rate 
Baseline Change From Baseline 
Mean SE Mean SE Adj Mean* Tx Effect* p Value? 
Rest Heart Rate (beats/rain): Placebo Group, n = 58; Zatebradine Group, n = 64 
Week 1 
Placebo 
Zatebradine 
Week 2 
Placebo 
Zatebradine 
Week 4 
Placebo 
Zatebradine 
83.9 1.40 - 1.4 1.04 -0 .5  
80.0 1.94 -11.5 1.20 -12.1 -11.7 <0.0001 
83.9 1.40 -2.7 1.20 -1.3 
80.0 1.94 -14.6 1.25 -14.3 -13.0 <0.0001 
83.9 1.40 -Z3 1.60 -1.6 
80.0 1.94 -12.9 1.23 -13.0 -11.4 <0.0001 
Heart Rate (beats/rain) atEnd of Last Comparable Stage of Exercise: Placebo Group, n = 57; 
Zatebradine Group, n = 64 
Week 1 
Placebo 
Zatebradine 
Week 2 
Placebo 
Zatebradine 
'treek 4 
Jlacebo 
Zatebradine 
120.3 2.40 -1.8 1.06 - 1.5 
120.6 1.98 -15.9 1.02 -15.6 -14.1 <0.0001 
120.1 2.22 -3.1 1.20 -2.5 
120.5 1.87 -16.4 0.9g -15.5 -13.0 <0.0~11 
119.4 2.39 -3,4 1.21 -4.0 
12I).1 I.$ ~ ) -16.7 1.16 -16.8 - 12.~, <~.~(K 
Heart Rate (beats/rain) atEnd of Exercise: Placebo Group, n = 58; Zatcbradine Group, n = 64 
Week 1 
Placebo 133.2 2.09 -1.0 1.28 0.6 
Zatebradme 131.8 1.87 -33.0 1,24 -12,0 -12.6 <0.0001 
Week 2 
Placebo 133.2 2.09 - ~.8 1,41 0.2 
Zatebradine 131.8 1.87 - 119 1.37 - 10,8 - 10.9 <0.0001 
Week 4 
Placebo 133.2 2.09 -0.6 1.54 0.8 
*Adjusted (Adj) for center and baseline. ?Zatebradine v rsus placebo.-qX = treatment. 
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Table 4. Effect of Placebo and Zatebradine (5 mg) on Systolic Blood Pressure 
Baseline Change From Baseline 
No. of Pts Mean SE lvlean SE Adj Mean* Tx Effect* p Valuer 
Rest Blood Pressure (mm Hg) 
Week 1 
Placebo 
Zatebradine 
Week 2 
Placebo 
Zatebradine 
Week 4 
Placebo 
Zatebradine 
59 126.2 2.04 -0.4 1.70 -0.7 
64 127.2 2.22 1.9 1.93 1.2 1.9 0.45 
58 126.4 2.08 0.2 1.81 0.4 
63 127.1 2.25 1.4 1.65 1.3 0.9 0.71 
57 126.8 2.08 0.9 1.71 -0.9 
64 127.2 2.22 0.9 1.89 -0.9 0.0 1.00 
Blood Pressure (mm Hg) at End of Last Comparable Stage of Exercise 
Week 1 
Placebo 57 
Zatebradine 64 
Week 2 
Placebo 57 
Zatebradine 63 
Week 4 
Placebo 55 
Zatebradine 64 
157.7 3.09 -0.9 2.10 -1.3 
159.9 2.99 2.5 2.22 1.7 3.0 0.32 
157.6 3.16 -2.9 2.25 -4.7 
159.6 2.97 - 1.8 1.84 -3.8 0.9 0.74 
158.0 3.18 -3.3 2.41 -7.2 
159.6 2.96 0.3 1.93 -2.2 5.0 0.085 
Blood Pressure (ram Hg) at End of Exercise 
Week 1 
Placebo 58 167.3 3.19 0.6 2.30 0.8 
Zatebradine 63 168.5 2.80 5.5 1.79 5.2 4.4 0.12 
Week 2 
Placebo 57 167.4 3.24 -0.5 2.38 -2.5 
Zatebradine 62 168 3 2.84 2.8 2.29 -0.1 2.4 0.48 
Week 4 
Placebo 55 166.7 3.23 -0.4 2.62 -3.3 
Zatebradine 63 168.5 2.80 2.0 1.88 -0.3 3.0 0.33 
*Adjusted (Adj) for trial center and baseline, tZatebradine v rsus placebo. Pts = patients; Tx = treatment. 
that compared zatebradine with either diitiazem (11) or pla- 
cebo (12) in patients with angina pectoris, only diltiazem 
improved total exercise time over placebo baseline values. 
Potential biases. There are at least two possible xplana- 
tions for our findings: 1) The primary response variable 
(e.g., exercise duration) using the Bruce protocol might not 
be sufficiently sensitive to the reduction in cardiac ischemia 
expected to result from a decrease in heart rate of 12 to 
14 beats/min. We previously reported (13) the limitations of 
this protocol for evaluating anti-ischemic treatments. 2) The 
reduction in heart rate might offset by an increase in other 
determinants of maximal ox3'gen consumption. Although 
systolic blood pressure was the only other index measured 
and rate pressure product declined, it is possible that 
ventricular preload or contractility increased. 
Clinical implications. Despite the theoretic benefit of us. 
ing bradycardic agents in the treatment of angina, especially 
those that lack negative inotropic effects and cardiac onduc- 
tion depressant actions, perhaps heart rate reduction alone is 
not enough to provide a long-acting antianginal benefit. 
Beta-blockers (2) and the calcium channel blockers 
verapamil and diltiazem (3) are bradycardic drugs which 
manifest an antianginal benefit. In addition to their brady- 
cardic actions, each of these agents has negative inotropic 
activity that may produce a more important anti-ischemic 
action than previously thought in patients with chronic 
angina. 
In contrast to our study, when nifedipine is combined with 
a beta-blocker, there are additive ffects ,on exercise tolerance 
greater than with either treatment alone (14). In addition, the 
combination of dihydropyridine amlodipine with a beta- 
blocker in patients with chronic angina pectoris also provides 
added antianginal and anti-ischemic efficacy compared with 
either drug used alone (15). 
In a clinical comparison of propranolol with other beta- 
blockers having less negative inotropic action but similar 
bradycardic activity, Pepine and Walker (16) demonstrated 
that propranolol had a greater antianginal effect. In patients 
with refractory angina pectoris and medication-induced brady- 
cardia, Moss et ai. (17) were able to demonstrate he effec- 
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Table 5. Effect of Placebo and Zatebradine (5 mg) on Anginal Attacks and Nitroglycerin Consumed 
Baseline Change From Baseline 
No. of Pts Mean SE Mean SE p Value* 
No. of Anginal Attacks/Week 
Week 2 
Placebo 58 
Zatebradine 64 
Week 4 
Placebo 58 
Zatebradine 64 
2.53 0.42 0.33 0.35 
1.59 0.32 -0.55 0.29 0.016 
2.53 0.42 -0.22 0.35 
1.59 0.32 -0.80 0.27 0.0058 
No. of Nitroglycerin Tablets Consumed/Week 
Week 2 
Placebo 58 
Zatebradine 64 
Week 4 
Placebo 58 
Zatebradine 64 
1.48 0.35 0.45 0 38 
0.73 0.17 -0.27 0.19 0.035 
1.48 0.35 0.14 0.37 
0.73 0.17 -0.23 0.22 0.086 
*Zatebradine v rsus placebo. Pts = patients. 
tiveness of a transvenous pacemaker toprevent severe brady- 
cardia combined with augmented antianginal therapy. In their 
study, the rate of the implanted emand pacer was set at 60 to 
72 beats/min, which allowed increases in doses of beta- and 
calcium channel blockers. A long-term remission in symptoms 
was observed and no patient developed heart failure. It would 
be interesting toexamine whether a nonvasodilating treatment 
intervention with negative inotropic activity only (e.g., a so- 
dium channel blocking agent, left bundle branch block from 
right ventricular pacing) and no effect on heart rate could have 
antianginal efficacy. 
Conclusions. Our results indicate that pure sinus node 
inhibition with the bradycardic agent zatebradine probably 
does not provide sufficient antianginal nd anti-ischemic effects 
to be useful for long-term treatment in patients with chronic 
stable angina who are taking nifedipine. However, investiga- 
tors are exploring the utility of zatebradine and other sirius 
node blocking agents as short-term treatments in both oral and 
intravenous forms in a number of other settings, uch as acute 
myocardial infarction and perioperative tachycardia (18-20). 
Furthermore, these agents may prove useful in controlling the 
untoward tachycardia induced by anesthetic and inotropic 
agents, which is especially important in the treatment of patients 
with acutely decompensated congestive heart failure (18). 
Appendix 
Study Investigators and Participating Institutions 
Baltimore, Maryland: David A. Goldscher, MD, Metropolitan 
Medical Associates. Auburn, Maine: Robert J. Weiss, MD, Andros 
Coggin Cardiology Associates. Bronx, New York: Salvatore Chiaramida, 
MD, Our Lady of Mercy Medical Ce~.ter; William H. Frisbman, MD, 
Hospital of the Albert Einstein College of Medicine. Guinesville, Florida: 
Carl J. Pepine, MD, University of Florida JHM Health Center. Houston, 
Texas: Luis A. Campos, MD, Med-Tech, ,c. Melrose Park, Illinois: 
Jeffrey G. Shanes, MD, Gottlieb Professional Building. Milwaukee, 
Wisconsin: John Wynsen, MD, Zablocki Veterans Administration Med- 
ical Center. Oklahoma City, Oklahoma: Steven Chrysant, MD, Okla- 
homa Cardiovascular and Hypertension Center. Orlando, Florida: Cur- 
tis J. Weaver, MD, Florida Heart Group. Red Wing, Minnesota: 
Donald L. Brans, MD, Interstate Medical Center. Sacramento, Califor- 
nia: Ezra Amsterdam, MD, University of California-Davis Medical 
Center. Salem, Massachusetts: Harvey Zarren, MD, Cardiolo~ Physi- 
cians, Inc. San Diego, California: Donald O'Haire, PhD, Center for 
Clinical Research; William A. Pitt, MD, Southern California Cardiology 
Medical Group, Inc. Thousand Oaks, California: Irving Loh, MD, 
HCA Los Robles Regional Medical Center. Tucson, Arizona: Frank 
Marcus, MD, Division of Cardiology, University of Arizona Health 
Sciences Center. 
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